HCPLive Network

FDA Approves Ravicti for Urea Cycle Disorders

 
FDA Approves Ravicti for Urea Cycle DisordersFRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.

These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia build-up can lead to coma, brain damage, or death, the FDA said Friday in a news release.

Ravicti is a liquid taken three times daily with meals. It's been approved for people whose disorders cannot be managed by a protein-restricted diet or amino acid supplements alone, the agency said.

Ravicti was compared to another UCD drug in a clinical study involving 44 adults. The most common side effects of the new drug were diarrhea, flatulence, and headache.

Ravicti is marketed by Hyperion Therapeutics, based in San Francisco.
 

More Information

Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Xi E. Zheng, MD, PhD, shares her views on young-onset colorectal cancer at 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
In what could be New York City’s first case of Ebola, a doctor identified by the NY Post as Craig Spencer, 33, MD an emergency medicine physician at New York Hospital/Columbia-Presbyterian was rushed to a special Ebola unit at city-run Bellevue Hospital Center in Manhattan. Spencer returned 10 days ago from a stint as a volunteer with Doctors without Borders, caring for Ebola victims in Guinea, one of three West African nations with major outbreaks.
Patients diagnosed with diabetic retinopathy may be able to get a sense of how their condition has progressed without having to leave the comfort of their own home.
Monitoring devices among intensive care patients set off 2.5 million alarms in one month at a U.S. hospital, a new study of "alarm fatigue" reveals. The research was published online Oct. 22 in PLOS ONE.
While in-office visits may still be best, virtual analysis may be a valuable option in atopic dermatitis care, according to a new study published online Oct. 22 in JAMA Dermatology.
After weight-loss surgery, some patients may be at risk for developing severe headaches, a new study suggests. The report was published online Oct. 22 in Neurology.
The US health care system ranks last compared to other industrialized nations when it comes to affordability and patient access, according to a new survey published in the Oct. 23 issue of the New England Journal of Medicine.
More Reading